Accuray Incorporated - Asset Resilience Ratio

Latest as of June 2021: 3.32%

Accuray Incorporated (ARAY) has an Asset Resilience Ratio of 3.32% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Accuray Incorporated strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$15.94 Million
Cash + Short-term Investments

Total Assets

$480.10 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2005–2021)

This chart shows how Accuray Incorporated's Asset Resilience Ratio has changed over time. See ARAY equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Accuray Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Accuray Incorporated stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $15.94 Million 3.32%
Total Liquid Assets $15.94 Million 3.32%

Asset Resilience Insights

  • Limited Liquidity: Accuray Incorporated maintains only 3.32% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Accuray Incorporated Industry Peers by Asset Resilience Ratio

Compare Accuray Incorporated's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.84%
Novocure Ltd
NASDAQ:NVCR
Medical Devices 43.72%
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
Medical Devices 49.23%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 39.15%
Anteris Technologies Global Corp
AU:AVR
Medical Devices 33.27%
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236
Medical Devices 25.01%
Tellgen Corp
SHE:300642
Medical Devices 9.96%
EBR Systems Inc
AU:EBR
Medical Devices 54.70%

Annual Asset Resilience Ratio for Accuray Incorporated (2005–2021)

The table below shows the annual Asset Resilience Ratio data for Accuray Incorporated.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2021-06-30 3.32% $15.94 Million $480.10 Million --
2018-06-30 0.00% $0.00 $378.73 Million --
2017-06-30 5.88% $23.91 Million $406.46 Million -4.19pp
2016-06-30 10.07% $47.24 Million $469.03 Million -3.61pp
2015-06-30 13.68% $64.31 Million $469.97 Million -2.38pp
2014-06-30 16.07% $79.55 Million $495.19 Million -5.17pp
2013-06-30 21.24% $101.08 Million $475.93 Million +20.91pp
2012-06-30 0.33% $1.56 Million $473.17 Million -0.37pp
2011-06-30 0.70% $3.17 Million $455.78 Million -37.26pp
2010-06-30 37.95% $99.88 Million $263.18 Million +14.40pp
2009-06-30 23.56% $64.63 Million $274.39 Million -5.44pp
2008-06-30 28.99% $85.54 Million $295.00 Million +28.99pp
2006-06-30 0.00% $1.00K $138.62 Million -0.18pp
2005-06-30 0.18% $158.00K $86.86 Million --
pp = percentage points

About Accuray Incorporated

NASDAQ:ARAY USA Medical Devices
Market Cap
$39.90 Million
Market Cap Rank
#23360 Global
#5021 in USA
Share Price
$0.34
Change (1 day)
+4.26%
52-Week Range
$0.27 - $1.85
All Time High
$7.46
About

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation t… Read more